Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Show more

100 Campus Drive, Florham Park, NJ, 07932, United States

https://www.phathompharma.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

817.1M

52 Wk Range

$2.21 - $18.31

Previous Close

$10.37

Open

$10.56

Volume

1,395,321

Day Range

$10.33 - $11.00

Enterprise Value

898.6M

Cash

130M

Avg Qtr Burn

-5.001M

Insider Ownership

4.53%

Institutional Own.

81.73%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details Intestinal infection, Gastroesophageal reflux disease, Esophagitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker) Details Eosinophilic Esophagitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.